• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Delcath Systems Inc.

    5/16/25 4:15:55 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    8-K
    NASDAQ false 0000872912 0000872912 2025-05-15 2025-05-15
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2025

     

     

    Delcath Systems, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-16133   06-1245881

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    566 Queensbury Avenue  
    Queensbury, New York   12804
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (212) 489-2100

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities pursuant to Section 12 (b) of the Act:

     

    Title of Each Class

     

    Trading

    Symbol(s)

     

    Name of Each Exchange

    on Which Registered

    Common Stock, $0.01 par value   DCTH   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Omnibus Equity Incentive Plan

    At the 2025 annual meeting of stockholders held on May 15, 2025 (the “Annual Meeting”), the stockholders of Delcath Systems, Inc. (the “Company”) approved an amendment to (i) the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 EIP”) to increase by 2,200,000 the number of shares of the Company’s common stock, $0.01 par value (the “Common Stock”) available thereunder and (ii) the Company’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”) to increase by 300,000 the number of shares of Common Stock available thereunder.

    A more detailed summary of the material features of the 2020 EIP, as amended, and 2021 ESPP, as amended, including the terms of stock option grants thereunder, is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 1, 2025 (the “2025 Proxy Statement”). That summary and the foregoing descriptions are qualified in their entirety by reference to the text of the 2020 EIP, as amended, and 2021 ESPP, as amended, which are attached as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders

    At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the 2025 Proxy Statement. Of the 33,927,205 shares of the Common Stock and outstanding and convertible preferred stock eligible to vote as of the record date, 22,755,045 shares, or approximately 67.1%, were present or represented by proxy at the Annual Meeting.

    The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

    Proposal 1. Stockholders elected the following nominees to serve as Class I directors on the board of directors of the Company (the “Board”) until the Company’s 2028 Annual Meeting or until their successors have been duly elected and qualified. The voting results for such nominees were as follows:

     

    Director Name    Votes For      Votes Withheld      Broker Non-
    Votes
     

    Gerard Michel

         15,966,658        96,373        6,692,014  

    Gilad Aharon

         15,945,595        117,436        6,692,014  

    Proposal 2. Stockholders approved the amendment to the 2020 EIP to increase by 2,200,000 the number of shares of Common Stock available under thereunder. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    12,443,374   2,876,487   742,169   6,693,015

    Proposal 3. Stockholders approved the amendment to the 2021 ESPP to increase by 300,000 the number of shares of Common Stock available under thereunder. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    15,835,603   106,523   101,794   6,711,125

    Proposal 4. Stockholders ratified the selection by the Audit Committee of the Board of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2025. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    22,591,488   159,518   4,039   N/A


    Proposal 5. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-
    Votes
    14,977,421   227,471   868,469   6,681,684

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit

    No.

       Description
    10.1    Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended
    10.2    Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, as amended
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 16, 2025   DELCATH SYSTEMS, INC.
        By:  

    /s/ David Hoffman

        Name:   David Hoffman
        Title:   General Counsel, Chief Compliance Officer and Secretary
    Get the next $DCTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Czerepak Elizabeth

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/19/25 4:10:12 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Sylvester John Richard

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/19/25 4:10:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Salamon Steven A J

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/19/25 4:10:13 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Delcath with a new price target

      Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

      6/28/24 8:18:39 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Delcath with a new price target

      Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:58:22 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity resumed coverage on Delcath with a new price target

      Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

      7/26/22 9:10:21 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    SEC Filings

    See more
    • Delcath Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/22/25 7:15:23 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Delcath Systems Inc.

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/16/25 4:15:55 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Delcath Systems Inc.

      10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 9:25:44 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

      SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 7:02:01 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Financials

    Live finance-specific insights

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

      3/6/25 8:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

      NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

      3/18/24 5:20:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      1/23/24 4:36:46 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Systems Issues Full Year 2025 Guidance

      2025 Full Year Total Revenue Guidance of $94 to $98 million Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access. 2025 Full Year Financial Guidance The Company's financial outlook for fiscal year 2025 is as follows: Total CHEMOSAT and HEPZATO KIT revenue of $94 to $98 million, an increase of more than 150% over 2024 Gross margins between 83% t

      5/22/25 7:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PH

      5/15/25 4:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025. The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equi

      5/9/25 5:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 8:00:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 7:44:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      12/14/23 4:20:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care